RxDoctor Payments Data

Kimberly Kessler

Family · Princeton, WVNPI 1679262968

Payments from drug & device makers

$3,675in general payments, 2019–2025

Across 171 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$688
  • AstraZeneca$685
  • Otsuka America Pharmaceutical, Inc.$655
  • Boehringer Ingelheim$626
  • Travere Therapeutics, Inc.$357
  • Novartis$254
  • plus $411 from 7 others

What the payments were for

  • Food & beverage$3,65599%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,675 in reported general payments places this provider in the 85th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$38,696
Medicare patients
231
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$49,890
JardianceEmpagliflozin52$40,781
OzempicSemaglutide18$28,729
KerendiaFinerenone18$18,825
Calcitriol122$2,441
Febuxostat11$1,086
Allopurinol163$1,005
Amlodipine Besylate72$614
Losartan Potassium66$535
Metolazone19$422
Lisinopril51$292
Irbesartan27$276
Vitamin D2Ergocalciferol (Vitamin D2)15$114
Glipizide24$86
Clonidine Hcl15$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$685$49,89065 claims
Boehringer IngelheimJardiance$626$40,78152 claims
Novo NordiskOzempic$92$28,72918 claims
BayerKerendia$688$18,82518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,507 family providers in West Virginia.

Other family in Princeton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →